Abstract
Purpose: This phase II trial investigated the efficacy and safety of Genolimzumab (GB226) in patients with previously treated, PD-L1-positive recurrent or metastatic cervical cancer.
Methods: We conducted a two-stage, phase II trial to enroll patients who had disease progression after first-line platinum-containing chemotherapy. Genolimzumab was administered intravenously at a dose of 3 mg/kg every two weeks until disease progression, unacceptable toxic effects, or withdrawal. The primary endpoint was Independent Review Committee (IRC)-assessed confirmed objective response rate (ORR) per RECIST version 1.1. Secondary endpoints included duration of response (DOR), overall survival (OS), and progression-free survival (PFS).
Results: 169 patients were enrolled between May 2019 and January 2022. In 100 efficacy-evaluable patients, the ORR was 18% (95% CI, 11.03–26.95) and the disease control rate was 41% (95% CI, 31.26–51.29). Median PFS was 1.91 months and median OS was 16.69 months. Among 123 safety-evaluable patients, 78.9% experienced treatment-related adverse events (TRAEs), most commonly hypothyroidism (24.4%) and anaemia (21.1%).
Conclusions: Genolimzumab as a second-line or later therapy demonstrates promising, durable clinical activity and favourable tolerability for patients with PD-L1-positive recurrent or metastatic cervical cancer.
Introduction
Cervical cancer remains a significant global health challenge, particularly in developing countries like China, where it accounts for a substantial portion of cancer-related deaths. While first-line treatments typically involve platinum-based chemotherapy, patients who experience recurrence or metastasis have limited effective options following treatment failure. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have emerged as a promising therapeutic strategy. This study evaluates Genolimzumab, a recombinant humanized anti-PD-1 monoclonal antibody developed in China, as a potential second-line treatment for this patient population.
Methods
This multicenter, open-label, single-arm, two-stage Phase II trial enrolled patients with histologically confirmed cervical cancer that progressed after at least one line of platinum-based therapy. Patients were required to be PD-L1-positive, defined by a Combined Positive Score (CPS) ≥ 1 using the Ventana SP263 assay. Genolimzumab was administered at 3 mg/kg every two weeks. The primary endpoint was ORR assessed by an IRC using RECIST v1.1 criteria.
Results
Efficacy Outcomes
In the 100 efficacy-evaluable patients, the confirmed ORR was 18%, including 5 complete responses and 13 partial responses. The disease control rate (DCR) was 41%. The median duration of response (DOR) was not reached during the follow-up period, indicating durable benefits for responders. The median progression-free survival (PFS) was 1.91 months, and the median overall survival (OS) was 16.69 months.
Subgroup analysis revealed that patients with a CPS ≥ 20 had a significantly higher ORR (23.7%) compared to those with a CPS between 1 and 20 (14.5%). Patients with squamous cell carcinoma and those who had only one prior line of therapy also showed better outcomes.
Safety Profile
Among 123 safety-evaluable patients, 78.9% experienced TRAEs. Grade 3/4 TRAEs occurred in 20.3% of patients. The most frequent events were endocrine-related, including hypothyroidism (24.4%) and hyperthyroidism (13.8%), as well as anaemia (21.1%). These results are consistent with the known safety profile of PD-1 inhibitors and were generally manageable with standard care.
Discussion
Genolimzumab demonstrates competitive efficacy and a manageable safety profile in the second-line setting for PD-L1-positive cervical cancer. The ORR of 18% and median OS of 16.69 months compare favorably to the 14.3% ORR and 11-month median OS reported for pembrolizumab in the KEYNOTE-158 study. This suggests Genolimzumab is a highly viable alternative, particularly in regions where access to other immunotherapies may be limited. The study highlights the importance of PD-L1 expression levels, with higher CPS scores correlating with improved response rates.
Conclusion
Genolimzumab provides a promising and tolerable treatment option for patients with PD-L1-positive recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy. It shows particularly durable clinical activity in patients with squamous cell carcinoma, one prior line of therapy, or a CPS ≥ 20. Future research should focus on randomized Phase III trials and combination strategies to further enhance clinical outcomes.
Summary updated